IGC Pharma weighs civil claims after Andrew Left securities fraud conviction tied to 2018 short campaign

• IGC Pharma is reviewing potential civil claims tied to the 2018 short campaign highlighted in the federal jury verdict in United States v. Andrew Left.
• Andrew Left was convicted of one count of securities fraud scheme, 12 securities fraud counts; IGC was cited as a targeted issuer.
• IGC is assessing possible damages tied to alleged market-value harm, reputational impact, operational disruption, legal and regulatory costs.
• Indictment alleged trading generated more than $3.8 million profit for a hedge fund, more than $1.1 million for Left.
• SEC order said Anson entities paid USD 2.25 million penalties; trading around an IGC tweet generated about USD 500,000 profit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607290830ACCESSWRNAPR_____1197865) on July 29, 2026, and is solely responsible for the information contained therein.